Adaptimmune Therapeutics PLC (ADAP) Insider Trading -- Recent Executive & Director Transactions

8 insiders reported 24 Form 4 transactions for Adaptimmune Therapeutics PLC (ADAP) over the past 18 months (most recent 2025-09-03). Recent activity: Wood Gavin (Chief Financial Officer) Sell 96,000 shares, Bertrand William C JR (Chief Operating Officer) Sell 207,000 shares, Behbahani Ali (Director) Sell 4.8M shares, Behbahani Ali (Director) Sell 14.7M shares, EcoR1 Capital, LLC (Insider) Sell 33.9M shares. Source: SEC Form 4.

DateInsiderTitleTypeSharesValue
2025-09-03Wood GavinChief Financial OfficerSell96,000$960
2025-08-29Bertrand William C JRChief Operating OfficerSell207,000$2,070
2025-08-19Behbahani AliDirectorSell4.8M$48,282
2025-08-19Behbahani AliDirectorSell14.7M$146,718
2025-07-30EcoR1 Capital, LLCInsiderSell33.9M$3.7M
2025-07-30EcoR1 Capital, LLCInsiderSell2.7M$268,746
2025-07-30EcoR1 Capital, LLCInsiderSell27.4M$2.7M
2025-01-17Lunger JohnChief Patient Supply OfficerSell5,584$3,239
2025-01-17Rawcliffe AdrianChief Executive OfficerSell30,601$17,749
2025-01-17Norry ElliotChief Medical OfficerSell5,584$3,239
2025-01-17Bertrand William C JRChief Operating OfficerSell5,584$3,239
2025-01-15Norry ElliotChief Medical OfficerSell8,124$4,793
2025-01-15Norry ElliotChief Medical OfficerSell4,268$2,518
2025-01-15Norry ElliotChief Medical OfficerSell9,803$5,588
2025-01-15Lunger JohnChief Patient Supply OfficerSell4,268$2,518
2025-01-15Lunger JohnChief Patient Supply OfficerSell5,471$3,228
2025-01-15Lunger JohnChief Patient Supply OfficerSell9,803$5,588
2025-01-15Piccina CintiaChief Commercial OfficerSell12,991$7,405
2025-01-15Bertrand William C JRChief Operating OfficerSell4,268$2,518
2025-01-15Bertrand William C JRChief Operating OfficerSell5,471$3,228
2025-01-15Bertrand William C JRChief Operating OfficerSell9,803$5,588
2025-01-15Rawcliffe AdrianChief Executive OfficerSell12,539$7,398
2025-01-15Rawcliffe AdrianChief Executive OfficerSell17,934$10,581
2025-01-15Rawcliffe AdrianChief Executive OfficerSell29,096$16,585

Source: SEC Form 4 filings · as of 2025-09-03